Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant

Journal of Heart and Lung Transplantation

Volumn 31, Issue 7, 2012, Pages 686-693

  Everitt, Melanie D ^a,c   Hammond, M Elizabeth H ^c   Snow, Gregory L ^c   Stehlik, Josef ^a,c   Revelo, Monica P ^b,c   Miller, Dylan V ^b,c   Kaza, Aditya K ^b,c   Budge, Deborah ^c   Alharethi, Rami ^c   Molina, Kimberly M ^a,c   Kfoury, Abdallah G ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

antibody mediated; cardiac allograft vasculopathy; heart transplant; pediatric; rejection

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES; BIOPSY; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; INFANT; INTERNATIONAL COOPERATION; MALE; MYOCARDIUM; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; RISK FACTORS; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84861847432     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2012.03.009     Document Type: Article

References (33)

1. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989;8:430-43. (Pubitemid 20044096)
2. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to coronary artery disease. J Heart Lung Transplant 2003;22:58-69. (Pubitemid 36071418)
3. Kfoury AG, Renlund DG, Snow GL, et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant 2009;28:51-7.
4. Miller LW, Wesp A, Jennison SH, et al. Vascular rejection in heart transplant recipients. J Heart Lung Transplant 1993;12(suppl): S147-52. (Pubitemid 23123854)
5. Lones MA, Czer LSC, Trento A, et al. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant 1995;14:151-62.
6. Hammond MEH, Hansen JK, Spencer LS, et al. Vascular rejection in cardiac transplantation: histologic, immunopathologic, and ultrastructural features. Cardiovasc Pathol 1993;2:21-34.
7. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody- mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009;28:417-22.
8. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006;25:1277-82. (Pubitemid 44767730)
9. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710-20. (Pubitemid 41641841)
10. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011;30:252-69.
11. Berry G, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011;30:601-11.
12. Revelo MP, Stehlik J, Miller D, et al. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant 2011;30:144-50.
13. Hammond MEH, Stehlik J, Snow G, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant 2005;24: 2015-21. (Pubitemid 41814718)
14. Berry GJ, Angelini A, Burke M, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011;30:601-11.
15. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010;29:717-27.
16. Casarez TW, Perens G, Williams RJ, et al. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant 2007;26:114-9. (Pubitemid 46136037)
17. Kucirka LM, Maleszewski JJ, Segev DL, et al. Survey of North American pathologist practices regarding antibody-mediated rejection in cardiac transplant biopsies. Cardiovasc Pathol 2011;20:132-8.
18. Cheung CY, Chan HW, Liu YL, et al. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis. Nephrology 2009;14:758-63.
19. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporine microemulsion. Pediatr Transplant 2005;9:498-503. (Pubitemid 41153271)
20. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86. (Pubitemid 44030320)
21. Knight SR, Russell NK, Barcena L, et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009;87:785-94.
22. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006;6:993-7. (Pubitemid 44356649)
23. Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. J Heart Lung Transplant 2010;29:625-32.
24. Everitt MD, Pahl E, Schechtman KB, et al. Rejection with hemodynamic compromise in the current era of pediatric heart transplantation: a multi-institutional study. J Heart Lung Transplant 2011;30:282-8.
25. Nicolas RT, Kort HW, Balzer DT, et al. Surveillance for transplant coronary artery disease in infants, child, and adolescent heart transplant recipients: an intravascular ultrasound study. J Heart Lung Transplant 2006;25:921-7. (Pubitemid 44144591)
26. Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant 2005;24:645-51. (Pubitemid 40798245)
27. Kirk R, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010;29:1119-28.
28. Irving C, Carter V, Parry G, et al. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival. Pediatr Transplant 2011;15:193-7.
29. Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010;29:1277-85.
30. Narayan S, Tsai EW, Zhang Q, et al. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transplant 2011;15:E1-7.
31. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011;72:5-10.
32. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011;11:312-9.
33. Kfoury A, Hammond M, Snow G, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular rejection and antibody-mediated rejection. J Heart Lung Transplant 2009;28:781-4.